<DOC>
	<DOCNO>NCT01672476</DOCNO>
	<brief_summary>A Randomized , Double-Blind , Multicenter , phase III Study Evaluate Antihypertensive Efficacy Safety Fimasartan ( BR-A-657·K ) 30mg Compared Placebo Patients Mild Moderate Essential Hypertension</brief_summary>
	<brief_title>A Multicenter , Phase 3 Study Evaluate Antihypertensive Efficacy Safety Fimasartan ( BR-A-657∙K ) 30mg Compared Placebo Patients With Mild Moderate Essential Hypertension</brief_title>
	<detailed_description>After subject sign informed consent voluntarily , take hypertension medication , go screening period 7 day include wash-out period . After screen wash-out period , subject take placebo 14 day ( Maximum 21 day ) , evaluate suitability Inclusion Exclusion criterion . Patients , evaluate proper subject clinical trial , allocate experimental group ( Fimasartan 30mg ) Control group ( Placebo group ) Reference group ( Valsartan 80mg ) randomly ratio 2:2:1 investigational drug administer daily study period ( 8 week ) . Subjects visit investigator twice treatment period , take investigational drug 4 week , 8 week . The placebo period single-blinded treatment allocation study double-blinded .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Subjects agree participate clinical trial submit write informed consent 2 . Subjects age 20 75 year 3 . Essential hypertension patient measure 90mmHg , less 110mmHg sit diastolic blood pressure ( SiDBP ) baseline ( Day 0 ) 4 . Subject consider understand clinical trial , cooperative , able followedup whole clinical trial period 1 . Severe hypertension patient : 110mmHg mean SiDBP and/or 185mmHg mean Sitting systolic blood pressure ( SiSBP ) 2 . Patients orthostatic hypotension sign symptom 3 . Patients secondary hypertension 4 . Patients measure difference mean blood pressure one arm SiDBP 10mmHg SiSBP 20mmHg screen baseline visit 5 . Patients stop administration hypertension medication clinical trial period , take hypertension medication except investigational drug 6 . Patients significant investigationsabnormal renal function ( Creatinine 1.5 time upper limit normal ) , abnormal liver function ( AST , ALT 2 time upper limit normal ) , severe fatty liver disease need medication 7 . Patients clinically significant investigation laboratory test screen visit 8 . Patients surgical medical disease able affect absorption , distribution , metabolism excretion 9 . Patients severe insulin dependent uncontrolled diabetes mellitus ( HbA1c &gt; 9 , regimen change oral hypoglycemic agent , use insulin ) 10 . Patients severe heart disease , ischemic heart disease within 6 month , peripheral vascular disease , Percutaneous transluminal coronary angiography ( PTCA ) , Coronary artery bypass graft ( CABG ) 11 . Patients significant ventricular tachycardia , atrial fibrillation , atrial flutter significant arrhythmia 12 . Patients hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically significant aortic valve mitral valve disease 13 . Patients severe cerebrovascular disease 14 . Patients waste disease , autoimmune disease , connective tissue disease present and/or previous 15 . Patients know severe malignancy retinopathy 16 . Patients hepatitis B C HIV positive reaction 17 . Patients medical history malignant tumor within 5 year , except local basal cell carcinoma skin 18 . Patients story evidence alcohol drug abuse within 2 year 19 . Patients history allergic reaction angiotensin II antagonist 20 . Patients chronic inflammation disease need chronic inflammation therapy 21 . Childbearing breastfeed woman 22 . Female plan become pregnancy possibility pregnancy n't prevent conception acknowledge method 23 . Patients take medicine within 12 week screen visit go progress clinical trial 24 . Patients significant investigationsHypokalemia ( Less 3.5 mmol/L ) , Hyperkalemia ( exceed 5.5 mmol/L ) 25 . Patients sodium ion body fluid deplated able correct 26 . Subject judge unsuitable participate clinical trial investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Fimasartan</keyword>
</DOC>